Demographic and Clinical Factors Related to Carboplatin Toxicity

Abstract

01 Clinical Lung Cancer, Vol. 10, No. 5, E5, 2009; DOI: 10.3816/CLC.2009.n.054 Demographic and Clinical Factors Related to Carboplatin Toxicity Sanjay J. Ayirookuzhi, Jerry McLarty, Richard P. Mansour, Glenn M. Mills LSU Health Sciences Center, Division of Hematology-Oncology/Feist-Weiller Cancer Center, Shreveport, LA Background: Carboplatin is a commonly used drug in stage III/IV non–small-cell lung cancer (NSCLC). Myelosuppression is a common toxicity of carboplatin, and this study aimed to assess the relationship between different demographic and descriptive factors and myelosuppression. Patients and Methods: Data from patients with stage III and IV NSCLC seen between January 1, 1999, and December 31, 2007, were analyzed. Patients who received concurrent radiation, had died before the first cycle was completed, or who had missing laboratory values were excluded. Only the first cycle of the carboplatin-based regimen was used for analysis with nadir platelets, hemoglobin, and white blood cell counts (WBCs) used as endpoints. SPSS software was used for statistical analysis including Pearson correlation, analysis of covariance (ANCOVA), independent t tests, and multivariate linear regression models. Results: Of the 216 patients initially abstracted for analysis, only 132 patients qualified for analysis. Demographically, 71 were Caucasian, and the rest were African-American, while 92 were male. The t test to indicate whether nadirs were different by stage were significant for platelets (P = .015) and WBC (P < .0001) but not hemoglobin. t test for race was significant for nadir platelets (P = .008) and hemoglobin (P = .004) but not for nadir WBC. ANCOVA for nadir platelets was significantly related to baseline platelet levels (P < .0001), stage (P = .012) and approached significance for stage with sex (P = .054). ANCOVA performed for nadir hemoglobin was significantly related to race (P = .015), while ANCOVA for nadir WBC was statistically significantly related to BSA (P = .026), baseline WBC count (P < .000), race (P = .017), and stage at diagnosis (P = .045). Carboplatin dose was not found to be statistically significantly related to nadir platelet, WBC, or hemoglobin in these models. Conclusion: Carboplatin is a myelosuppressive drug, and a number of factors are related to its toxicity. Meeting Abstracts Abstracts From: The 10th International Lung Cancer Congress June 17-20, 2009; Kohala Coast, HIs From: The 10th International Lung Cancer Congress June 17-20, 2009; Kohala Coast, HI Program Directors: David R. Gandara, MD; Roy S. Herbst, MD, PhD Clinical Lung Cancer September 2009 | E5 Available Online at www.cigjournals.com